IL270781A - Treatment of depressive disorders - Google Patents

Treatment of depressive disorders

Info

Publication number
IL270781A
IL270781A IL270781A IL27078119A IL270781A IL 270781 A IL270781 A IL 270781A IL 270781 A IL270781 A IL 270781A IL 27078119 A IL27078119 A IL 27078119A IL 270781 A IL270781 A IL 270781A
Authority
IL
Israel
Prior art keywords
treatment
depressive disorders
depressive
disorders
Prior art date
Application number
IL270781A
Other languages
English (en)
Hebrew (he)
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of IL270781A publication Critical patent/IL270781A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL270781A 2017-05-24 2019-11-20 Treatment of depressive disorders IL270781A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762510481P 2017-05-24 2017-05-24
US15/933,673 US20180338959A1 (en) 2017-05-24 2018-03-23 Treatment of depressive disorders
PCT/US2018/033848 WO2018217718A1 (en) 2017-05-24 2018-05-22 Treatment of depressive disorders

Publications (1)

Publication Number Publication Date
IL270781A true IL270781A (en) 2020-01-30

Family

ID=64395877

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270781A IL270781A (en) 2017-05-24 2019-11-20 Treatment of depressive disorders

Country Status (10)

Country Link
US (4) US20180338959A1 (https=)
EP (2) EP3630065A4 (https=)
JP (2) JP2020520963A (https=)
KR (1) KR20200018485A (https=)
CN (2) CN115105499A (https=)
AU (1) AU2018272819A1 (https=)
CA (1) CA3064299A1 (https=)
IL (1) IL270781A (https=)
MX (1) MX393452B (https=)
WO (1) WO2018217718A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
HK1258616A1 (zh) 2016-03-08 2019-11-15 Sage Therapeutics, Inc. 神经活性类固醇、组合物、及其用途
US10987303B2 (en) * 2018-05-02 2021-04-27 LifeMax Laboratories, Inc. Extended release suspension formulation of lurasidone
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
WO2020168337A1 (en) 2019-02-17 2020-08-20 Magid Abraham Compositions and methods for treatment of depression and other disorders
KR102085938B1 (ko) * 2019-11-04 2020-03-06 한국메탈실리콘 주식회사 실리콘 복합체 제조방법
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
AR031473A1 (es) * 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
DK1641456T3 (da) * 2003-06-25 2010-06-21 Lundbeck & Co As H Gaboxadol til behandling af depression og andre affektive lidelser
CL2004001603A1 (es) * 2003-06-25 2005-05-27 Lundbeck & Co As H Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico.
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
US20090048288A1 (en) * 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
US10628156B2 (en) * 2013-07-09 2020-04-21 Texas Instruments Incorporated Vector SIMD VLIW data path architecture
DK3151832T3 (da) * 2014-06-06 2021-06-14 Ovid Therapeutics Inc Fremgangsmåder til øgning af tonisk hæmning og behandling af sekundær søvnløshed
IL256912B2 (en) * 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
WO2017027249A1 (en) * 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
KR20220035195A (ko) * 2019-07-15 2022-03-21 오비드 테라퓨틱스 인크. 치료적 치료를 위한 가복사돌을 포함하는 약학적 제제

Also Published As

Publication number Publication date
EP3630065A1 (en) 2020-04-08
EP3939587A1 (en) 2022-01-19
US20180338959A1 (en) 2018-11-29
US20190117633A1 (en) 2019-04-25
KR20200018485A (ko) 2020-02-19
AU2018272819A1 (en) 2019-12-05
JP2020520963A (ja) 2020-07-16
CN110996910A (zh) 2020-04-10
US20210379028A1 (en) 2021-12-09
US20200179351A1 (en) 2020-06-11
JP2023061957A (ja) 2023-05-02
WO2018217718A1 (en) 2018-11-29
MX2019014024A (es) 2020-02-17
EP3630065A4 (en) 2021-03-24
MX393452B (es) 2025-03-24
CN115105499A (zh) 2022-09-27
CA3064299A1 (en) 2019-11-29

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
IL273693A (en) Treatment of inflammatory disorders
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL270781A (en) Treatment of depressive disorders
GB201804514D0 (en) Treatment of pyroptosis
GB201608046D0 (en) Treatment of complement-mediated disorders
IL269604A (en) Pentides for the treatment of autoimmune diseases
ZA201705847B (en) Treatment of pain
GB201612043D0 (en) Composition for treatment of disorders
GB201804515D0 (en) Treatment of necroptosis
EP3258930A4 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
LT3458067T (lt) Neurologinių sutrikimų gydymas
GB201607388D0 (en) Treatment of impulsivity-related disorders
GB201714307D0 (en) Treatment of neurodegenerative diseases
IL270362B (en) Glaucoma treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
PT3713572T (pt) Tratamento da taquicardia
IL257935A (en) Treatment of bone growth disorders
GB201717629D0 (en) Treatment of unipolar depressive disorder
ZA202002910B (en) Treatment of skin disorders
GB201713760D0 (en) Treatment of epilepsy
GB201604359D0 (en) Treatment of tissue disorders
GB201714311D0 (en) Treatment of neurodegenerative diseases
GB201714303D0 (en) Treatment of neurodegenerative diseases
GB201602784D0 (en) New treatment of CFTR-related disorders